Biosimilars innovation to transform Vietnamese pharma

On his first business trip to Vietnam, Russell Miller, vice president of Global Sales and Marketing at Enzene Biosciences, shared with VIR’s Ho Ha the company’s ambition to reshape the global biosimilars landscape through innovation and advanced manufacturing.

As one of India’s fastest-growing biopharmaceutical firms, Enzene is pursuing a model that combines affordability with world-class quality, an approach that aligns with Vietnam’s efforts to expand access to essential medicines and develop a more self-reliant healthcare industry.

He further discussed how Enzene’s next-generation manufacturing platforms are transforming the economics of biologics production, and why Vietnam, with its emerging market potential and growing R&D capacity, could become a strategic partner in the company’s global expansion.

Vice president Miller is a pharmaceutical expert with more than 20 years of experience driving growth and technology in the biopharmaceutical sector. His expertise spans the entire drug development process, from analytics and formulation to large-scale manufacturing.

In his current role at Enzene Biosciences, Miller focuses on developing strategic partnerships and expanding access to advanced biomanufacturing services worldwide. His leadership reflects Enzene’s broader vision of leveraging technology and innovation to deliver high-quality, affordable biologics to global markets.

This is your first visit to Vietnam. After a busy week of meetings, what left the strongest impression on you?

What impressed me most was the opportunity to engage with senior officials from the Drug Administration of Vietnam (DAV) and to meet several dynamic Vietnamese pharmaceutical companies. These exchanges gave me a clear sense of the country’s determination to strengthen its healthcare system and accelerate the development of its pharmaceutical industry. I believe Enzene’s experience and biopharma solutions can play a meaningful role in improving both affordability and healthcare quality for Vietnamese patients.

I was also struck by the warmth and hospitality of the Vietnamese people. Everyone was incredibly welcoming and eager to share their culture through wonderful local cuisine. I particularly enjoyed Hanoi’s Pho and other traditional dishes. Today, we even tried a vegetarian restaurant, the creativity in using fresh ingredients was truly impressive.

With more than two decades of experience in the pharmaceutical industry, could you share some of the key lessons from your career journey, and what ultimately inspired you to join Enzene Biosciences?

I began my career as a scientist in research and development, spending the first six years deeply involved in formulation and process innovation. Over time, I transitioned into commercial and strategic roles at companies such as Vectura, ANI Pharmaceuticals, Scotwork, and most notably Catalent Pharma Solutions, where I spent more than 16 years. These experiences gave me a comprehensive view of the pharmaceutical value chain – from R&D and clinical trials to biologics development and customer engagement – all guided by a commitment to improving patient outcomes.

What inspired me to join Enzene was the company’s clear vision for innovation and its strong technological foundation. Our CEO’s forward-looking approach, combined with Enzene’s proprietary, commercially proven technology platform, offers real potential to transform the way biologics are developed and manufactured. I saw in Enzene a rare opportunity to bring together scientific excellence, scalability, and affordability in a way that truly advances access to modern therapies.

The most important lesson I’ve learned in over 20 years is the power of effective planning. In pharma, navigating complex regulatory landscapes and managing risks requires meticulous preparation. Only with precise planning can we overcome global challenges and deliver meaningful benefits to patients worldwide.

In your view, what differentiates Enzene from competitors in the biosimilars and CDMO space? How does your technology optimise costs and enhance production efficiency?

That’s an excellent question. What truly sets Enzene apart is our clear vision and commitment to improving access to high-quality biologics. Our goal is to make advanced therapies more affordable, ensuring that patients, especially those in markets with limited healthcare access, can benefit from life-changing treatments.

Innovation lies at the core of our operations, guiding every stage from research and development to commercial manufacturing. Enzene’s technological foundation, combined with a culture of scientific creativity, allows us to maintain a pioneering edge while opening new opportunities for collaboration across the biopharmaceutical sector.

A central pillar of this innovation is our proprietary Fully-Connected Continuous Manufacturing (FCCM) platform, which seamlessly integrates all stages of biologics production – from upstream processing to downstream purification. Traditionally, biologics manufacturing requires multiple large bioreactors operating in sequence, often involving up to six massive tanks. This setup consumes substantial space, capital, and time, and introduces operational risks.

With FCCM, fresh media is continuously fed into cell cultures, linking reaction, separation, and purification into a single streamlined process. This approach maximises reactor utilisation, increases output by up to tenfold, significantly reduces costs, and minimises risk, representing a major step forward in biomanufacturing efficiency.

For example, a 2,000-litre reactor previously required around 5,000 sq ft of manufacturing space. With FCCM, only 1,500 sq.ft is needed, saving 70 per cent in infrastructure costs. The system is also eco-friendly: higher productivity, lower cogs, consistent quality, and sustainable operations without the performance decline typical of batch processes.

With FCCM, we not only improve production efficiency but also accelerate patient access to vital biologics – with better quality and greater sustainability.

Source : https://vir.com.vn/